This Is MS Multiple Sclerosis Knowledge & Support Community

Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), February 2009
First Received: May 3, 2006 Last Updated: June 9, 2009 History of Changes
Sponsored by: National Institute of Neurological Disorders and Stroke (NINDS)

Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00321568

Purpose
This study will evaluate the ability of magnetic resonance imaging (MRI) using different magnet strengths (1.5, 3 and 7 Tesla) to detect damage in different parts of the brain in patients with multiple sclerosis. The higher the Tesla, the greater the ability to see brain changes. Healthy subjects will also be studied to compare findings in patients with those of normal volunteers.
Healthy normal volunteers and patients with multiple sclerosis 18-65 years of age may be eligible for this study. Patients should have minimal clinical disability. Candidates are screened with a medical history, physical examination, and blood and urine tests.
Participants undergo three MRI examinations. The first is on a 1.5 Tesla machine. The second and third - at 3 Tesla and 7 Tesla - are done within 30 days of the first. Each procedure takes about 2 hours. Before and after the 7 Tesla examination, subjects have an electrocardiogram (EKG), their blood pressure and temperature are measured and a blood sample is drawn.
MRI uses a magnetic field and radio waves to produce images of body tissues and organs. This test has several advantages over x-ray methods, such as the ability to see more clearly inside the brain and to see chemical changes that might occur in specific neurological diseases. Also, since x-rays are not used, there is no radiation risk. Radio waves are generated and changes in magnetic fields are measured and analyzed by computer. For the procedure, the subject lies on a table that is moved into a metal cylinder (the MRI scanner) that has a strong magnetic field. Earplugs are worn to muffle loud thumping noises caused by the electrical switching of the radio frequency circuits. During the MRI, subjects receive an injection of a contrast agent called Gadolinium, which brightens the images.
...


Condition
Multiple Sclerosis



Study Type: Observational
Official Title: An Exploratory Study on Detection of Cortical and White Matter Damage in Patients With Multiple Sclerosis Using Magnetic Resonance Imaging at 7 Tesla


Resource links provided by NLM:


MedlinePlus related topics: MRI Scans Multiple Sclerosis Neurologic Diseases
U.S. FDA Resources


Further study details as provided by National Institutes of Health Clinical Center (CC):


Estimated Enrollment: 265
Study Start Date: May 2006
Estimated Study Completion Date: January 2008
Estimated Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Detailed Description:
OBJECTIVE: Among the factors contributing to the poor identification of grey and white matter pathology of multiple sclerosis (MS) patients, the low signal-to-noise ratio and consequential poor resolution of magnetic resonance imaging (MRI) obtained at conventional magnetic fields (i.e. 1.5 Tesla) play a significant role. Preliminary results suggest that 7T-MRI has the capability to disclose characteristics of chronic white matter lesions' heterogeneity in MS, not seen at lower field MRI. We now aim to extend those results by investigating whether lesions' heterogeneous appearance pertain not only to chronic lesions, i.e. those studied thus far, but also to newly formed lesions, i.e. those enhancing upon gadolinium injection. The latter can be identified only by imaging at 7T with contrast injection those MS patients known to already have active lesions.
STUDY POPULATION: Up to 145 patients (age range: 18-65, range in the Expanded Disability Status Scale: 0-4.5) with definite MS according to Poser criteria or other diseases of the central nervous system resembling MS from an imaging stand point and up to 120 age/gender-matched healthy volunteers will be enrolled.
DESIGN: Patients previously shown to meet both the clinical and MRI criteria for MS and an equivalent number of gender- and age-matched healthy volunteers will be studied. Initially, both patients and healthy individuals will have conventional 1.5Tesla MRI T1-weighted scans without contrast, whereas patients will also have post-contrast scans. Next, both groups of subjects will be imaged on both the 3 Tesla and 7 Tesla MRIs in a random order.
In each 3 Tesla and 7 Tesla MRI study the examination will include the following sequences; 3 dimensional inversion-recovery-prepared fast spoiled gradient recalled images, 3Dfluid-attenuated inversion recovery and double inversion recovery in addition to T1 and T2 conventional weighted images.
A second group of 15 patients will be imaged. Each patient may undergo a standard 3T MRI within the two weeks before the 7T MRI (if needed, as no information regarding his/her disease status are otherwise available from 3T MRI performed under other NIB protocols). The latter will allow ascertaining in advance his/her status of lesions activity, thus providing an adequate number of patients with active lesions imaged at the 7T. Each patient may need to repeat his/her scan three times in case of magnetic instability during image acquisition. Additional 3T and 7T MRIs will be performed after 1 and 6 months to follow active lesions evolution over time.
OUTCOME MEASURES: The number of cortical lesions as well as white matter and deep grey abnormalities will be computed on images obtained at 1.5, 3 and 7 Tesla MRIs. The study will not aim at conducting a formal comparison of cortical or white matters lesions seen on 3 Tesla and 7 Tesla. Instead, the goal is to provide preliminary information that can be used to design a formal analysis of the sensitivities of the two platforms in studying those abnormalities seen in MS. Active lesions found to be conspicuous upon contrast injection will be compared between T1 and gradient echo images at 7T.
Additionally, active lesions evolution over time at 7T will be evaluated.
Eligibility


Ages Eligible for Study: 18 Years to 65 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes

Criteria
INCLUSION CRITERIA:
Diagnosis of MS.
Age between 18 and 65.
Central nervous system white matter and grey matter focal disease which may mimic MS in its imaging appearance.
EXCLUSION CRITERIA:
Pregnancy or breastfeeding since contrast is harmful in people who are breastfeeding.
Unable to provide informed consent.
Permanent tattooed makeup (eyeliner, lip, etc) or general tattoos.
Any non-organic implant or any other device such as: cardiac pacemaker, insulin infusion pump, implanted drug infusion device, cochlear, otologic, or ear implant, transdermal medication patch (Nitro), any metallic implants or objects, body piercing(s), bone/joint pin, screw, nail, plate, wire sutures or surgical staples, shunt.
Cerebral aneurysm clips, shrapnel or other metal imbedded in your body (such as from war wounds or accidents).
Previous work in metal fields or with machines that may have left any metallic fragments in or near your eyes.
Severe auto accidents in the past with non-certainty that a metal object is still present in the subject's body.
Any psychological contraindications for MRI (e.g., suffer from claustrophobia).
A candidate subject is excluded if in the judgment of the Principal Investigator, protocol participation would place the subject to substantially increased acute medical risk.
Individuals with hearing problems will be excluded
HEALTHY VOLUNTEERS INCLUSION CRITERIA:
1. Age between 18 and 65
HEALTHY VOLUNTEERS EXCLUSION CRITERIA:
1. Same as for patients.
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00321568


Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010


Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
More Information

Additional Information:
NIH Clinical Center Detailed Web Page

Publications:
BROWNELL B, HUGHES JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962 Nov;25:315-20. No abstract available.
Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999 Jan;122 ( Pt 1):17-26.
Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001 Sep;50(3):389-400.

Study ID Numbers: 060154, 06-N-0154
Study First Received: May 3, 2006
Last Updated: June 9, 2009
ClinicalTrials.gov Identifier: NCT00321568 History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Multiple Sclerosis
Magnetic Resonance
MRI
Magnetic Field
Multiple Sclerosis
MS



Study placed in the following topic categories:
Autoimmune Diseases
Multiple Sclerosis
Demyelinating Diseases
Demyelinating Autoimmune Diseases, CNS
Sclerosis
Brain Injuries
Autoimmune Diseases of the Nervous System



Additional relevant MeSH terms:
Pathologic Processes
Autoimmune Diseases
Immune System Diseases
Demyelinating Diseases
Nervous System Diseases
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Sclerosis
Autoimmune Diseases of the Nervous System



ClinicalTrials.gov processed this record on June 19, 2009


Back to top of Main Content



Contact Help Desk
Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
U.S. National Institutes of Health, U.S. Department of Health & Human Services,
USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act








Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
This study is currently recruiting participants.
Verified by Office of Rare Diseases (ORD), March 2009
First Received: July 5, 2000 Last Updated: March 10, 2009 History of Changes
Sponsors and Collaborators: National Center for Research Resources (NCRR)
University of Pennsylvania

Information provided by: Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier: NCT00006060

Purpose
OBJECTIVES: I. Determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, T2 and enhanced T1 lesion volume, and the magnetization transfer ratio histogram parameters, and correlate these measurements with clinical measures of disability in patients with multiple sclerosis. II. Measure the quantity of whole brain N-acetylaspartate in patients with multiple sclerosis and compare these values to those from age matched controls. III. Determine the correlation between specific neuropsychological tests which assess global cognitive functioning and the quantitative measurements taken in these patients in this study.


Condition Intervention
Multiple Sclerosis
Drug: standard gadolinium contrast



Study Type: Observational


Resource links provided by NLM:


MedlinePlus related topics: Multiple Sclerosis
U.S. FDA Resources


Further study details as provided by Office of Rare Diseases (ORD):


Estimated Enrollment: 100
Study Start Date: April 1999
Detailed Description:
PROTOCOL OUTLINE:
Patients undergo magnetic resonance imaging and spectroscopy with standard gadolinium contrast followed by neuropsychological testing every 6 months for 5 years. An equal number of age and sex matched healthy patients act as a control group and undergo magnetic resonance imaging and spectroscopy without standard gadolinium contrast every 6 months for 5 years.
Eligibility


Ages Eligible for Study: 20 Years to 70 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes

Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of multiple sclerosis Relapsing-remitting defined as 2 exacerbations and a worsening of neurologic function over 1 day followed by at least 30 days of no progression OR Secondary-progressive defined as increase of at least 1.0 unit on Expanded Disability Status Scale (EDSS) in past 2 years with or without exacerbations
--Prior/Concurrent Therapy--
Biologic therapy: Prior interferon beta 1A, 1B, or glatiramer acetate No concurrent interferon beta 1A, 1B, or glatiramer acetate
Endocrine therapy: Concurrent oral and IV corticosteroids allowed
--Patient Characteristics--
Performance status: EDSS no greater than 7.0
Hematopoietic: No hematologic dysfunction including hemolytic anemia
Hepatic: No hepatic dysfunction
Renal: No renal dysfunction
Cardiovascular: No cardiac pacemaker
Other: Not pregnant or nursing Negative pregnancy test No intracranial clips, metal implants, or external clips within 10 mm of head No metal in eyes No known gadolinium texaphyrin allergy No known claustrophobia
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006060


Contacts
Contact: Robert I. Grossman, MD 212-263-3269


Locations
United States, New York
New York University Medical Center Recruiting
New York, New York, United States, 10016
Contact: Lois J. Mannon, BSRT, (MR) (R) CCRC 212-263-3783 lois.mannon@med.nyu.edu
Principal Investigator: Robert I. Grossman, MD

Sponsors and Collaborators
National Center for Research Resources (NCRR)
University of Pennsylvania
Investigators
Study Chair: Robert I. Grossman, MD New York University School of Medicine

More Information

No publications provided

Study ID Numbers: 199/15245, UPSM-704-0, UPSM-070300, UPSM-NS-29029
Study First Received: July 5, 2000
Last Updated: March 10, 2009
ClinicalTrials.gov Identifier: NCT00006060 History of Changes
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
multiple sclerosis
neurologic and psychiatric disorders
rare disease



Study placed in the following topic categories:
Autoimmune Diseases
Multiple Sclerosis
Demyelinating Diseases
Mental Disorders
Rare Diseases
Demyelinating Autoimmune Diseases, CNS
Sclerosis
Autoimmune Diseases of the Nervous System



Additional relevant MeSH terms:
Pathologic Processes
Autoimmune Diseases
Immune System Diseases
Demyelinating Diseases
Nervous System Diseases
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Sclerosis
Autoimmune Diseases of the Nervous System



Comparing Magnetic Resonance Imaging/Spectroscopy Techniques
This study is currently recruiting participants. Verified by National Institutes of Health Clinical Center (CC), December 2008
First Received: November 3, 1999 Last Updated: June 9, 2009 History of Changes
Sponsored by: National Institutes of Health Clinical Center (CC)

Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001219

Purpose
Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) are diagnostic tests that allow researchers to look at different chemical properties of tissue. Magnetic resonance imaging and spectroscopy studies can be used to gather or evaluate information about various aspects of patient's bodies or to monitor changes in the biochemistry and physiology of patient's bodies.
Unlike other diagnostic techniques (CT scan and PET scan) MRI and MRS do not use ionizing radiation. Some studies have shown that MRI is more effective at distinguishing normal parts of the anatomy from abnormal anatomy, especially in the brain. MRI has become the diagnostic test of choice for evaluating patient with multiple sclerosis.
The purpose of this study is to evaluate normal volunteers and patients with a variety of diseases with magnetic resonance imaging. Researchers will attempt different magnetic resonance imaging methods and techniques as well as different levels of magnetic strength.


Condition
Healthy



Study Type: Observational
Official Title: Nuclear Magnetic Resonance Imaging/Spectroscopy at 1.5 and 3.0 Tesla


Resource links provided by NLM:


Genetics Home Reference related topics: ataxia-telangiectasia
MedlinePlus related topics: MRI Scans
U.S. FDA Resources


Further study details as provided by National Institutes of Health Clinical Center (CC):


Estimated Enrollment: 99999
Study Start Date: June 1987
Estimated Study Completion Date: June 1990
Estimated Primary Completion Date: June 1990 (Final data collection date for primary outcome measure)
Detailed Description:
MRI is a constantly evolving imaging modality and MR. Pulse sequences are often modified to improve their performance. However, many of these changes have not yet been approved by the FDA and therefore, are not considered standard of care. Some of these sequences require the use of new types of imaging coils, which are also investigational. The major purpose of this protocol is to inform patients undergoing MR scans in the Clinical Center that they may undergo scans that are not FDA approved and to get the patient's consent for this. This is not a formal research study since specific disease entities and specific pulse sequences are not studied in a systematic way. Rather, the purpose is to give NIH patients access to gradual improvements in MR technology that would otherwise not be available to them. A secondary purpose is to inform patients about the risks of MRI and gadolinium chelates which are commonly employed in MRI.
Eligibility


Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
INCLUSION CRITERIA:
All patients undergoing MRI in the Clinical Center.
Patients must be able to provide informed consents.
EXCLUSION CRITERIA:
No contraindications to MRI.
Inability to understand consent form or consent process and the absence of a suitable guardian.
Refusal to Participate.
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001219


Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010


Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
More Information

Additional Information:
NIH Clinical Center Detailed Web Page

Publications:
Frank JA, Dwyer AJ, Doppman JL. Nuclear magnetic resonance imaging in oncology. Important Adv Oncol. 1987;:133-74. Review.
Roschmann P, Tischler R. Surface coil proton MR imaging at 2 T. Radiology. 1986 Oct;161(1):251-5.
Kim EE, Pjura G, Lowry P, Verani R, Sandler C, Flechner S, Kahan B. Cyclosporin-A nephrotoxicity and acute cellular rejection in renal transplant recipients: correlation between radionuclide and histologic findings. Radiology. 1986 May;159(2):443-6.

Study ID Numbers: 870091, 87-CC-0091
Study First Received: November 3, 1999
Last Updated: June 9, 2009
ClinicalTrials.gov Identifier: NCT00001219 History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Surface Coils
T1-Weighted Images
T2-Weighted Images
Pulse Sequences
Spin Echo
Inversion Recovery
Partial Saturation
GRASS



Study placed in the following topic categories:
Ataxia-Telangiectasia
Healthy
Ataxia Telangiectasia



ClinicalTrials.gov processed this record on June 19, 2009



Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-Modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy (IRM 3T-SEP)This study is currently recruiting participants.
Verified by Hospices Civils de Lyon, March 2009
First Received: March 12, 2009 No Changes Posted
Sponsored by: Hospices Civils de Lyon

Information provided by: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT00861172
Purpose
It is difficult to determinate prognostic criteria of Multiple Sclerosis with conventional MRI insofar as physiopathology is not well-known: the precise sequences of events leading to plaque formation and axonal injury are still not completely understood.
Some elements involved in plaque formation can be studied thanks to MR techniques (cerebrospinal fluid and periveinular spaces, neuronal injury, microglia, and cerebral microcirculation's dysfunction). This study aims at giving a better understanding of MS plaques' physiopathology, using data from modern MRI through a longitudinal followed up with weakly MR 3T examination.


Condition Intervention
Lesions
Multiple Sclerosis
Procedure: 3T MR scanner



Study Type: Interventional
Study Design: Open Label, Uncontrolled, Single Group Assignment
Official Title: Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-Modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy


Resource links provided by NLM:


MedlinePlus related topics: Multiple Sclerosis
U.S. FDA Resources


Further study details as provided by Hospices Civils de Lyon:


Primary Outcome Measures:
Modification of MR parameters before and after the blood brain barrier disruption observed in newly enhancing lesion in MS. [ Time Frame: each week for 2 months, at 6 month and at 12 month ] [ Designated as safety issue: No ]



Secondary Outcome Measures:
Predictive scorers of plaque transformation in "black-holes", which correspond with a pejorative evolution of accurate lesions, also defined by a focal destruction of cerebral tissue. [ Time Frame: each week for 2 months, at 6 month and at 12 month ] [ Designated as safety issue: No ]

Relation between plaques development and cerebral venous structures. [ Time Frame: each week for 2 months, at 6 month and at 12 month ] [ Designated as safety issue: No ]


Estimated Enrollment: 10
Study Start Date: February 2009
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Experimental Procedure: 3T MR scanner
The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months. We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.
The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection.


Detailed Description:
The objective of this work are:
study weakly development of the active MS plaque with multimodal MRI parameters using advanced MRI techniques: Veinography/3D FLAIR, Diffusion (CDA), Perfusion (CBV, CBF, MTT) MR Spectroscopy (NAA, myo-inositol, choline, lactate…) and enhanced 3DT1 sequences.
define prognostic marker s of MS aggressiveness ("black holes")
Study development of MS plaque around venous structures.
Eligibility


Ages Eligible for Study: 18 Years to 50 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
Inclusion Criteria:
Age between 18 and 50 years.
Health coverage.
Any form of MS defined by Mc Donald's criteria (2005).
Patients having shown an enhanced plaque on a less than six month MRI examination.
Exclusion Criteria:
Pa tients with an immunomodulating therapy like natalizumab (Tysabri) and intravenous immunosuppressive therapies. Other therapies will not be excluded from this study. For patients treated by systemic corticotherapy, a one-month delay will be necessary before a MRI examination.
Cerebral microangiopathy (diabetes, arterial hypertension, vascularitis…)
Patient with classical MRI contraindication like pace-maker, cardiac valvulosis, claustrophobia, allergy to contrast agent …
Pregnancy or pregnancy desire.
Patient with a low creatinine clearance <60 ml/mn
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00861172


Contacts
Contact: Francois Cotton, Professor +33478861443 francois.cotton@chu-lyon.fr
Contact: Jean Roch +33478861443


Locations
France
Services de Neurologie A et Service de Neuroradiologie, Pôle transversal d'imagerie, Hôpital Neurologique Recruiting
BRON Cedex, France, 69677
Principal Investigator: Christian Confavreux, Pr
Sub-Investigator: Sandra Vukusic, MD
Sub-Investigator: Francoise Durand-Dubief, MD &n bsp;

Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: Francois Cotton, Pr Hospices Civils de Lyon

More Information

No publications provided

Responsible Party: Hospices Civils de Lyon ( Pr. Francois COTTON )
Study ID Numbers: 2008.532
Study First Received: March 12, 2009
Last Updated: March 12, 2009
ClinicalTrials.gov Identifier: NCT00861172 History of Changes
Health Authority: France: Afssaps - French Health Products Safety Agency

Keywords provided by Hospices Civils de Lyon:
Multiple sclerosis
Active plaque
Multimodal analysis
3T MRI
Weekly follow-up
Physiopathology
Physiopathology of active lesions formation in Multiple Sclerosis using multimodal MR sequences



Study placed in the following topic categories:
Imidacloprid
Autoimmune Diseases
Multiple Scle rosis
Demyelinating Diseases
Demyelinating Autoimmune Diseases, CNS
Sclerosis
Autoimmune Diseases of the Nervous System



Additional relevant MeSH terms:
Pathologic Processes
Autoimmune Diseases
Immune System Diseases
Demyelinating Diseases
Nervous System Diseases
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Sclerosis
Autoimmune Diseases of the Nervous System



ClinicalTrials.gov processed this record on June 19, 2009

Holly-
Thanks for posting the clinical trials.
These are great observational studies for perfusion, venous structure implication and brain changes in MS- as shown by MRI- but not really for CCSVI specifically. Maybe rename the thread, so there's no confusion. The only study for CCSVI currently is at Jacobs Neurological Institute at SUNY Buffalo.
Thanks!
cheer

The post name has been changed...yes they are observational but they are looking at the brains w/ higher resolution MRV and hopefully they should see the veins.

I could not find the Jacobs clinical trial listed on clinicaltrials.gov can anyone help w/ that so we know the same specs as the trials above?

In light of the jacobs trial, these may be a way to get copies of your brain MRV ...when contacting them, ask first and also ask about if they will/could look at the IJV